Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01904721 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
A Phase 2 study of Alopecia and Alopecia, Androgenetic, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 244
- Enrollment target
- 1
- Study location
NCT01904721: Completed Phase 2 study of Alopecia and Alopecia, Androgenetic, sponsored by Allergan.
NCT01904721 is a Phase 2 study of Alopecia and Alopecia, Androgenetic that has completed, run by Allergan. The registered enrollment target is 244 participants, above the 106-participant average among 13 other Alopecia trials with a reported enrollment target (130% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01904721, a Phase 2 study of Alopecia and Alopecia, Androgenetic, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 244 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia (AGA).
Primary Outcome
TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters squared (cm\^2). A positive change from Baseline indicated improvement (increase in the number of terminal hairs) and a negative change from Baseline indicated worsening (decrease in the number of terminal hairs).
Conditions Studied
Interventions
- DRUG Bimatoprost Solution 1
- DRUG Bimatoprost Solution 2
- DRUG Bimatoprost Vehicle
Study Locations (1)
Minnesota
- - Fridley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
What the finished NCT01904721 record still lists
NCT01904721 is an interventional study that assigns participants to a tested intervention. The registered 244 participants enrollment target is mid-sized for trials with a published cap, above the 106-participant average among 13 other Alopecia trials with a reported enrollment target (130% higher).
The record links to 3 conditions, with Alopecia appearing as the primary indexed condition, and to 3 interventions - of which Bimatoprost Solution 1 is the first listed.
NCT01904721 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT01904721 about?
NCT01904721 is a clinical study titled "A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)". This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia (AGA).
What is the current status of trial NCT01904721?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 244 participants. The study started on 2013-08. Estimated completion is 2015-01.
What conditions does trial NCT01904721 study?
This clinical trial studies the following conditions: Alopecia, Alopecia, Androgenetic, Baldness.
What interventions are being tested in trial NCT01904721?
The interventions under investigation include: Bimatoprost Solution 1 (DRUG), Bimatoprost Solution 2 (DRUG), Bimatoprost Vehicle (DRUG).
Who is sponsoring clinical trial NCT01904721?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01904721 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01904721's enrollment target sits among peer trials
244 3rd of 13 higher than 11 of 13 other Alopecia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alopecia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors
ACTIVE NOT RECRUITING · Phase 2
-
Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)
RECRUITING · NA
-
Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors
RECRUITING · NA
-
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
RECRUITING · NA
-
Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color
RECRUITING · NA
-
Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and Hair Regrowth in the Appalachian Highlands Region
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02227251 · 244 participants · Phase 2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT04317534 · 244 participants · Phase 2
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
- NCT04683250 · 244 participants · Phase 1
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
- NCT04686305 · 244 participants · Phase 1
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia